Introduction {#section5-1470320318755269}
============

Atrial fibrillation (AF) is a source of considerable morbidity and mortality. In 1995, Wijffels et al. revealed that AF modified atrial properties so that AF maintains itself more readily, a phenomenon called electrical remodeling and described as "AF begets AF."^[@bibr1-1470320318755269]^ The electric remodeling during AF involves decrease in the atrial effective refractory period (ERP), action potential (AP) duration,^[@bibr2-1470320318755269][@bibr3-1470320318755269][@bibr4-1470320318755269]-[@bibr5-1470320318755269]^ and/or ERP adaptation to heart rate,^[@bibr1-1470320318755269],[@bibr6-1470320318755269]^ as well as decreased atrial conduction velocity (CV).^[@bibr2-1470320318755269],[@bibr3-1470320318755269],[@bibr5-1470320318755269]^ Voltage-gated sodium channels are transiently activated on depolarization of the cardiac cell membrane and are responsible for the rapid upstroke of cardiac AP, and for rapid impulse conduction through cardiac tissue.^[@bibr7-1470320318755269],[@bibr8-1470320318755269]^ Inhibition of cardiac sodium current (I~Na~) slows down CV, which as a single factor reduces wavelength (defined as the product of CV and ERP) and should promote AF induction or atrial flutter.^[@bibr9-1470320318755269]^

Activation of the renin-angiotensin system (RAS) has been suggested to play a role in the genesis and perpetuation of AF through atrial remodeling, and experimental studies have validated the utilization of RAS inhibition for AF prevention.^[@bibr10-1470320318755269]^ Angiotensin II (Ang II), the major active component of RAS, can increase the intracellular free calcium, alters the potassium conductance, and induces the genesis of transient inward currents.^[@bibr11-1470320318755269]^ Ang II can also decrease SCN5A transcription and current through production of H~2~O~2~ resulting in nuclear factor kappa B (NF-κB) binding to the sodium channel promoter.^[@bibr9-1470320318755269]^ Therefore, Ang II has a high arrhythmogenic activity and may play an important role in the pathophysiology of atrial fibrillation, and inhibition of Ang II may prevent the development of atrial electrical remodeling (AER).^[@bibr10-1470320318755269]^

Angiotensin II receptor blockers (ARBs) are medications frequently used in the treatment of congestive heart failure and hypertension and have several cardiac electrophysiological effects. Previous studies have shown that the ARB irbesartan was found to contribute to maintenance of sinus rhythm after successful electrical cardioversion and prevented the shortening of the atrial ERP during rapid atrial pacing.^[@bibr10-1470320318755269],[@bibr12-1470320318755269]^ In addition, irbesartan suppresses atrial fibrosis and AF development in a canine atrial tachycardia remodeling model.^[@bibr13-1470320318755269]^ Furthermore, irbesartan attenuated the hypotonic solution-induced increase in rectifier potassium currents induced by stretching atrial myocytes.^[@bibr14-1470320318755269]^ Previous studies led to the conclusion that atrial electrical and structural remodeling could be prevented by irbesartan and Ang-(1--7); meanwhile, chronic rapid atrial pacing, a concomitant reduction in AF vulnerability in a canine model, could be observed.^[@bibr14-1470320318755269][@bibr15-1470320318755269][@bibr16-1470320318755269]-[@bibr17-1470320318755269]^ I~Na~ is essential for the heart conduction system, and slowing of intra-atrial conduction is one of the key factors for reentry and is necessary for AF induction or atrial flutter.^[@bibr6-1470320318755269]^ Nevertheless, the effects of irbesartan on I~Na~ have not been fully explored, which naturally led us to the present study. Therefore, we tested the hypothesis that treatment with irbesartan increases I~Na~ densities, which contributes to improving intra-atrial conduction and prevents the induction and promotion of AF. Thus, the goal of this study was to examine the effects of irbesartan on I~Na~ and messenger RNA (mRNA) expression of sodium channel in a canine model of rapid atrial pacing.

Materials and methods {#section6-1470320318755269}
=====================

Animal model {#section7-1470320318755269}
------------

Approval for use of the animals in this study was attained from the Experimental Animal Administration Committee of Tianjin Medical University and Tianjin Municipal Commission for Experimental Animal Control. Eighteen mongrel dogs of either sex, weighing between 11 and 15 kg, were randomly assigned to three groups. In the pacing+irbesartan group (*n* = 6), oral administration of irbesartan (60mg·kg^−1^·d^−1^) was continued to the end of the study. The dogs in the sham (*n* = 6) and pacing group (*n* = 6) did not receive irbesartan. Dogs within the pacing and pacing+irbesartan groups were paced at 500 beats per minute (bpm) (120 ms cycle length) with 0.2 ms square-wave pulses at twice-threshold current for 14 days. Sham animals were instrumented without pacing and were examined for 14 days following pacemaker insertion.

We used a previously described method to produce dogs with sustained AF.^[@bibr17-1470320318755269]^ In brief, all dogs were anesthetized with sodium pentobarbital (30 mg·kg^−1^, intravenously). Under sterile technique, a unipolar screw-in St. Jude J pacing lead was inserted through the right jugular vein and the distal end of the lead was screwed in the right atrium. Initial atrial capture was verified using an external stimulator (TOP2001, Hongtong Co, Shanghai, China). The proximal end of the pacing lead was connected to a tachy-pacing generator (made in Shanghai Fudan University, China), which was inserted into a subcutaneous pocket in the neck. Twenty-four hours was allowed for the lead to stabilize. The pacemaker was programmed to stimulate the atrium at 500 bpm (120 ms cycle length). Surface electrocardiograms (ECGs) were verified after 24 hours, and then every other day, to ensure continuous 1:1 atrial capture. Direct systolic blood pressure was determined during anesthesia at baseline, and 14 days following atrial pacing.

Single-cell electrophysiology {#section8-1470320318755269}
-----------------------------

The procedure for isolating cells was the same as used in previous research.^[@bibr17-1470320318755269]^ On study days, the dogs were anesthetized with pentobarbital and ventilated as above. A median sternotomy was performed. At room temperature the hearts were removed and immersed in Ca^2+^-free Tyrode's solution.

The left circumflex artery was cannulated, and the hearts were immersed in 4°C Ca^2+^-free Tyrode's solution for 5 minutes until cardiac arrest and the effluent was clear. Any leaking arterial branches were ligated using silk thread to ensure adequate perfusion. The tissue was then perfused at 25 ml/min with Ca^2+^-free Tyrode's solution for 20 minutes, followed by a 40-minute perfusion using the same solution containing collagenase (100 U/ml, CLSII, Worthington Biochemical, USA), and 0.5% bovine serum albumin (BSA) (Sigma Chemical Co, USA). The left atrium became opaque and mottled in appearance and tissue from a well-perfused region was removed using a forceps, gently triturated, and maintained at room temperature in a high-K^+^ storage solution.

High output of isolating atrial myocytes was obtained in our experiments. Only those quiescent rod-shaped cells lacking membrane deformities and showing clear cross-striations were studied. Five minutes after cell adhesion, cells were superfused with Tyrode's solution (3 ml/min) for 5 minutes, followed by extracellular solution for the recording of I~Na~ at the same velocity and time of flow. Recordings of I~Na~ were obtained 5 minutes following membrane rupture.

Data acquisition {#section9-1470320318755269}
----------------

Whole-cell I~Na~ was recorded at room temperature using the patch-clamp technique as described previously.^[@bibr17-1470320318755269]^ Borosilicate glass electrodes with tip resistances of 2.0 to 4.0 MΩ were connected to a patch clamp amplifier (Axopatch 200B, Axon Instruments, USA). Data were sampled by using an analog-to-digital converter (Digidata 1200, Axon Instruments, USA) and stored for subsequent analyses. Inactivation of current amplitude was measured on the basis of differences between the peak current and steady-state current at the end of a depolarizing pulse. After establishing the whole-cell configuration, series resistance (estimated from the decay of the capacitive transient) was typically two to three times the pipette resistance (\<6 MΩ) and was electronically compensated.

Several minutes after seal formation, the membrane was ruptured by gentle suction to establish the whole-cell configuration for voltage clamping. Series resistance (Rs) was electrically compensated to minimize voltage errors. Voltage command pulses were generated from the Digidata 1200 and controlled using pClamp7.0 software. Current signals were low-pass filtered at 0.5 kHz and the sampling frequency was 10 Hz for recording of I~Na~. To control for differences in cell size, current values were normalized to membrane capacitance (Cm), expressed as current densities (pA/pF).

Current-voltage relationships were determined in the extracellular solution over a voltage range of −80 to +60 mV with 10-mV increments. Voltage-dependent activation curves of I~Na~ were fitted with a Boltzmann equation: g/g~max~ (or I/I~max~) = 1/{1+exp\[(V--V~1/2~)/κ\]}, where V~1/2~ is the potential at which half maximum activation or inactivation occurs and κ is the slope factor. Steady-state inactivation was measured utilizing a standard dual-pulse protocol. Cells were held at −120 mV prior to evoking a 1-second conditioning pulse immediately followed by a 40-ms pulse to −40 mV with 5-mV increments to measure sodium current. Normalized currents were plotted as a function of conditioning step voltage and were fitted to a standard Boltzmann equation. Cells with significant leak currents were rejected and leakage compensation was not used for further study.

Solutions {#section10-1470320318755269}
---------

Ca^2+^-free Tyrode's solution contained (mM) KCl 5.4, MgCl~2~ 0.8, NaH~2~PO~4~ 0.33, NaCl 136, HEPES 10, glucose 10, and pH 7.4 adjusted with NaOH. High-K^+^ storage solution contained (mM) KCl 20, KH~2~PO~4~ 10, taurine 10, L-glutamic acid 70, EGTA 10, glucose 10, BSA 0.5% (5 mg/ml, Roche Group), and pH 7.4 adjusted with KOH. I~Na~ extracellular solution contained (mM) choline-Cl 110, CsCl 20, MgCl~2~ 1.0, HEPES 10, glucose 10, NaCl 10, CaCl~2~ 1.0, and pH 7.4 adjusted using NaOH. The pipette solution for I~Na~ recording was (mM) CsCl 20, tetraethyl ammonium chloride 20, aspartic acid 80, CsOH 80, MgCl~2~ 1, HEPES 10, EGTA 10, Mg~2~ATP 5, Na~3~GTP 0.1, Na~2~-phosphocreatine 5, and pH 7.25 adjusted with CsOH. All solutions used for dissection and perfusion were equilibrated using 100% O~2~.

RNA extraction and reverse transcription-polymerase chain reaction (RT-PCR) analyses {#section11-1470320318755269}
------------------------------------------------------------------------------------

Following cardiectomy, the left atria were excised for subsequent molecular biological studies. Specimens were snap-frozen in liquid nitrogen and stored separately at −80°C for further analyses. One aliquot of each tissue was used to investigate the mRNA expression of the Nav1.5 α subunit. Total RNA was extracted from 100 mg atrial tissues using a total RNA extraction kit (New Industry Co, Canada). Integrity of RNA was confirmed by agarose gel electrophoresis, the quantity of RNA was assessed spectrophotometrically (UV-240, Shimadzu Co, Japan) at a wavelength of 260 nm, and RNA was stored at −80°C for later analysis.

Specific oligonucleotide primer pairs for the amplification of Nav1.5 were designed according to GeneBank sequences. β-actin was utilized as the loading control. GeneBank accession numbers were NM-001002994 and AF021873 (β-actin). Gene-specific primers were designed using the Gene Runner software package. The specific primers were as follows: 5'-TGAATGTCCTCCTCGTCTG-3'/5'-TGTTGGTTGAAGTTGTCG-3' (Nav1.5 α subunit, 424 bp), 5'-GGACCTGACTGACTACCTC-3'/5'-ACTCCTGCTTGCTGATCC-3' (β-actin, 536 bp). Primers were purchased from Shanghai Yingjun Gen-Tech Ltd (Shanghai, China). A total of 200 ng of total RNA underwent RT-PCR using a commercially available kit (TaKaRa Co, Japan). PCR involved the following steps: initial denaturation at 94°C for 5 minutes followed by 37 cycles of denaturation for 40 seconds at 94°C, annealing for 40 seconds at 51°C, and elongation for 30 seconds at 72°C with a final extension at 72°C for 5 minutes. Product (5 μl) was analyzed using 1% agarose gel electrophoresis. The resultant target gene sequence was identified using Shanghai Yingjun Gen-Tech Ltd (Shanghai, China).

Statistical analyses {#section12-1470320318755269}
--------------------

In order to ensure data validity from voltage-clamp studies, similar numbers of cells from each heart were studied utilizing the same protocol (i.e. cells were distributed evenly across dogs). Grouped data are presented as mean±SEM. Statistical comparisons among groups were performed by analysis of variance. Differences with a two-tailed *p* \< 0.05 were considered statistically significant. All authors had full access to the data and take responsibility for their integrity.

Results {#section13-1470320318755269}
=======

Hemodynamic parameters {#section14-1470320318755269}
----------------------

No significant differences in ventricular rate or systolic blood pressure among the three groups were observed at baseline (*p* \> 0.05), with no differences found during pacing (*p* \> 0.05, [Table 1](#table1-1470320318755269){ref-type="table"}). Heart rate and blood pressure were also unchanged by rapid pacing within each group (*p* \> 0.05).

###### 

Hemodynamic parameters before and after pacing in each group.

![](10.1177_1470320318755269-table1)

  Grouping (*n* = 6 in each group)   Heart rate (bpm)   Systolic blood pressure (mmHg)                                     
  ---------------------------------- ------------------ -------------------------------- -------- ------------ ----------- --------
  Sham                               165.8±9.6          187.0±13.0                       \>0.05   134.0±7.0    138.0±6.0   \>0.05
  Pacing                             171.6±11.9         188.0±20.0                       \>0.05   140.0±10.0   138.0±8.0   \>0.05
  Irbesartan                         168.0±10.5         186.0±11.0                       \>0.05   135.0±10.0   136.0±9.0   \>0.05
  *P*                                \>0.05             \>0.05                                    \>0.05       \>0.05      

Sham: sham group; Pacing: pacing group; Irbesartan: pacing+irbesartan group; bpm: beats per minute.

I~Na~ densities {#section15-1470320318755269}
---------------

To avoid contaminating the effects of time-dependent changes in I~Na~ I-V, all protocols were performed by utilizing the same sequence: beginning with the I~Na~ density-voltage relationship, immediately followed by analyses of voltage-dependent inactivation.

[Figure 1](#fig1-1470320318755269){ref-type="fig"} illustrates the overall results for I~Na~ current densities. Peak I~Na~ density is shown as a function of test potential. The peak I~Na~ densities (as is shown in [Table 1](#table1-1470320318755269){ref-type="table"}) were −61.56±14.17 pA/pF (14 cells) in the sham, --32.65±10.92 pA/pF (28 cells) in the pacing, and −65.24±14.79 pA/pF (13 cells) in the pacing+irbesartan groups. I~Na~ was significantly decreased at all voltages (**--60 mV** to +35 mV) in the pacing group but the form of the I-V curve did not change compared with the sham group (*p* \< 0.05). The reduction of mean I~Na~ density was significantly prevented by irbesartan, and peak current densities increased by 99.82% compared with the pacing group (*p* \< 0.05). Cell capacitance averaged 69.15±19.16 pF (*n* = 14) in the sham, 73.48±13.01 pF (*n* = 28) in the pacing and 76.46±22.79 pF (*n* = 13) in the pacing+irbesartan groups.

![Mean current-voltage relationship of I~Na~ in the sham (*n* = 14), pacing (*n* = 28), and pacing+irbesartan (*n* = 13) groups. Currents were elicited from a high potential of −90 mV with 40 ms depolarizing steps to TP between −80 and +60 mV. I~Na~ was significantly decreased at all voltages (--60 mV to +35 mV) in the pacing group but the form of the I-V curve did not change compared with the sham group (*p* \< 0.05). The reduction of mean I~Na~ density was significantly prevented by irbesartan and peak current densities increased by 99.82% compared with the pacing group (*p* \< 0.05). I~Na~: cardiac sodium current; Sham: sham group; Pacing: pacing group; Irbesartan: pacing+irbesartan group; TP: test potential; pA/pF: current densities.](10.1177_1470320318755269-fig1){#fig1-1470320318755269}

Activation and inactivation characteristics of I~Na~ in isolated atrial myocytes {#section16-1470320318755269}
--------------------------------------------------------------------------------

[Figure 2](#fig2-1470320318755269){ref-type="fig"} depicts the steady-state activation curve of I~Na~. [Table 2](#table2-1470320318755269){ref-type="table"} summarizes the shifts in activation and inactivation variables. Voltage-dependent activation data were well-fitted using the Boltzmann equation. In the present experiment, rapid pacing did not alter half-activation voltage (V~1/2act~) (membrane voltage (V~m~) at which half-activation occurs) compared with the sham group (*p* \> 0.05). V~1/2act~ in the pacing+irbesartan group was more negative compared with the sham or pacing groups (*p* \< 0.05). The activation slope factor κ~act~, V~1/2inact~ (Vm at which half-inactivation occurs) and inactivation slope factor κ~inact~ were not significantly different among the three groups, indicating that rapid pacing and irbesartan have no significant effects on κ~act~, V~1/2inact~ or κ~inact~ of I~Na~ ([Figure 3](#fig3-1470320318755269){ref-type="fig"}).

![Mean values of voltage dependence of I~Na~ activation characteristics (I/I~max~). Rapid pacing did not alter the half activation voltage (V1/2~act~) compared with the sham group (*p* \> 0.05). V1/2~act~ in the pacing+irbesartan group was more negative compared with the sham or pacing groups (*p* \< 0.05). The activation slope factor κ~act~ was not significantly different among the three groups. Sham: sham group, Pacing: pacing group, Irbesartan: pacing+irbesartan group; TP: test potential.](10.1177_1470320318755269-fig2){#fig2-1470320318755269}

###### 

I~Na~ densities and steady-state activation and inactivation of I~Na~.

![](10.1177_1470320318755269-table2)

  Grouping (*n* = 6 in each group)   I~Na~ densities                                                       Activation   Inactivation                                                                                                    
  ---------------------------------- --------------------------------------------------------------------- ------------ -------------- ----------------------------------------------------------------- ---- ----------- ------------- ----
  Sham                               −61.56±14.17                                                          14           0.75±0.99      −50.68±4.45                                                       14   4.16±0.81   −84.89±4.05   12
  Pacing                             −32.65±10.92^[a](#table-fn2-1470320318755269){ref-type="table-fn"}^   28           1.77±1.31      −49.43±4.44                                                       28   4.57±0.48   −89.16±5.40   21
  Irbesartan                         −65.24±14.79^[b](#table-fn2-1470320318755269){ref-type="table-fn"}^   13           0.85±1.09      −55±5.35^[c](#table-fn2-1470320318755269){ref-type="table-fn"}^   13   4.61±0.76   −88.31±9.12   9

All data shown represent meant±SEM. ^a^*p* \< 0.01 vs. corresponding value in the sham group. ^b^*p* \< 0.05 vs. corresponding value in the pacing group. ^c^*p* \< 0.05 vs. corresponding value in the sham and pacing groups. Sham: sham group; Pacing: pacing group; Irbesartan: pacing+irbesartan group. I~Na~: cardiac sodium current; pA/pF: current densities; κ~act~: activation slope factor; V~1/2act~: half activation voltage.

![Mean values of voltage dependence of I~Na~ inactivation (I/I~max~). Sham: sham group; Pacing: pacing group; Irbesartan: pacing+irbesartan group; TP: test potential. The V1/2~inact~ and κ~inact~ were not significantly different among the three groups. V1/2~inact~: half-inactivation voltage; κ~inact~: inactivation slope factor.](10.1177_1470320318755269-fig3){#fig3-1470320318755269}

Nav1.5 α subunit mRNA expression {#section17-1470320318755269}
--------------------------------

I~Na~ in the heart is primarily generated by Nav1.5.^[@bibr18-1470320318755269]^ The α subunit is the principal component of Nav1.5 forming the pore and all essential gating elements, and is sufficient by itself for generating I~Na~ in heterologous expression systems. [Figure 4(a)](#fig4-1470320318755269){ref-type="fig"} shows a gel obtained by semiquantitative RT-PCR for the Nav1.5 α subunit. Lanes S, P and IB are PCR products from the sham, pacing and pacing+irbesartan groups obtained by the addition of 5 µl of the internal standard along with 5 µl of Nav1.5 α subunit PCR product, respectively. DL2000 is the DNA marker. The upper band in each lane represents the Nav1.5 α subunit mRNA product (424 bp), and the lower band is the internal standard signal (β-actin, 536 bp). [Figure 4(b)](#fig4-1470320318755269){ref-type="fig"} shows the mean±SEM of Nav1.5 α subunit mRNA levels in six hearts (one independent determination per heart) from each group of dogs. Nav1.5 α subunit mRNA expression was decreased by 54.83% after 14 days of rapid atrial pacing (*p* \< 0.05 vs. sham). The observed changes in mRNA levels are parallel to changes in I~Na~ densities. Irbesartan prevented the decrease of Nav1.5 α subunit mRNA expression compared with the paced group (*p* \< 0.05).

![(a) Atrial pacing decreased Nav1.5 α subunit mRNA expression in canine atria. Irbesartan increased Nav1.5 α subunit mRNA in paced atria. Columns and error bars indicate mean±SEM, respectively. β-actin was utilized as the loading control. (b) Atrial pacing decreased Nav1.5 α subunit mRNA expression in canine atria. Irbesartan increased Nav1.5 α subunit mRNA in paced atria. Columns and error bars indicate mean±SEM, respectively. \**p* \< 0.05 vs. corresponding value in the sham group, §*p* \< 0.05 vs. corresponding value in the pacing group. DL2000: DNA marker; S: sham group; P: pacing group; IB: pacing+irbesartan group (*n* = 6 in each group). Nav1.5: cardiac Na^+^ channels; mRNA: messenger RNA.](10.1177_1470320318755269-fig4){#fig4-1470320318755269}

Discussion {#section18-1470320318755269}
==========

Key findings {#section19-1470320318755269}
------------

A brief summary can be drawn from the key findings of the present study, that is, following pacing, I~Na~ density and mRNA expression of the Nav1.5 α subunit were decreased; irbesartan increased I~Na~ densities and hyperpolarized V~1/2act~. Meanwhile, it did not significantly affect κ~act~ or the inactivation characteristics of I~Na~ when compared with the pacing group. Irbesartan prevented downregulation of mRNA expression of the Nav1.5 α subunit in the pacing group.

Effects of rapid atrial pacing on I~Na~ and Nav1.5 α subunit gene expression {#section20-1470320318755269}
----------------------------------------------------------------------------

As the key structure of excitability in conduction of electrical impulses in cardiac tissue, the voltage-gated sodium channel is targeted by a series of anti-arrhythmics. The Nav1.5 α subunit is the principal component of cardiac Na^+^ channels, forming the pore and all essential gating elements and is sufficient to generate I~Na~ by itself in heterologous expression systems. Our previous research has shown that reductions in I~Na~ density and Nav1.5 α subunit gene expression potentially accounted for slowing of atrial conduction in a canine model of chronic AF.^[@bibr17-1470320318755269]^ Decreased conduction and ERP results in shorter wavelength (defined as the product of CV and ERP) and increases the number of wavelengths that can coexist in the given atrial dimension. Thus, it increases the likelihood of sustained AF.

Effects of irbesartan on I~Na~ and Nav1.5 α subunit mRNA expression {#section21-1470320318755269}
-------------------------------------------------------------------

Activation of the RAS contributes to development and maintenance of AF.^[@bibr19-1470320318755269],[@bibr20-1470320318755269]^ Ang II has been shown to stimulate various growth factors inducing development and maintenance of AER by acting on type 1 receptors^[@bibr10-1470320318755269]^ and may have cellular electrophysiologic effects on the modulation of ion channels in cardiac myocytes.^[@bibr21-1470320318755269],[@bibr22-1470320318755269]^ Ang II may increase intracellular calcium concentration^[@bibr23-1470320318755269],[@bibr24-1470320318755269]^ and intracellular calcium overload can downregulate Na^+^ channels, which may lead to decrease of I~Na~ and conduction delay deficits.^[@bibr25-1470320318755269]^ It is also reported that Ang II antagonists may exert favorable anti-arrhythmic effects in AF.^[@bibr26-1470320318755269]^ Li et al. found that imidapril markedly increases I~Na~ density of ventricular myocytes from healed myocardial infarction in rabbits.^[@bibr27-1470320318755269]^ Thus, they suggested that increased I~Na~ density may underlie the anti-arrhythmic effects of imidapril. We previously reported that Ang-(1--7) treatment significantly increased I~Na~ densities but had no effect on the expression of the *Nav1.5* gene.^[@bibr17-1470320318755269]^ However, the effects of irbesartan on I~Na~ or Nav1.5 mRNA expression are not clear. Our present data suggest that irbesartan can increase I~Na~ and Nav1.5 α subunit mRNA expression in a canine model of atrial tachycardia. We speculate that Ang II-induced intracellular calcium overload, which leads to decrease of I~Na~ and conduction delay deficits, may be partially responsible for this effect.^[@bibr25-1470320318755269]^

AF is generally considered to be a re-entrant arrhythmia, and the stability of AF is classically related to wavelength. As previously discussed, wavelength is defined as the product of CV and ERP. Therefore, modification of ERP or CV can affect AF vulnerability and stability.^[@bibr28-1470320318755269]^ Irbesartan increased I~Na~ and contributed to the increase of CV, the lengthening of reentry wavelength as well as the decreasing in the number of wavelengths. Thus, treatment with irbesartan could have the potential to reduce AF incidence. We also found that irbesartan upregulated Nav1.5 α subunit mRNA expression. These findings suggest that increased *Nav1.5* gene levels by irbesartan, at least in part, are potentially responsible for changes in I~Na~ densities.

Effects of irbesartan on activation and inactivation characteristics of I~Na~ {#section22-1470320318755269}
-----------------------------------------------------------------------------

Our previous research has shown that rapid atrial pacing has no effects on voltage-dependent activation of I~Na~, and Ang-(1--7) resulted in more negative test potentials.^[@bibr17-1470320318755269]^ The present study revealed that irbesartan had a similar effect as Ang-(1--7), which suggested an increased conductance at a particular membrane potential.^[@bibr29-1470320318755269]^ Such shifts induced faster activation kinetics and current augmentation at potentials closer to the threshold for activation and could actually indicate an enhancement of the current amplitude.^[@bibr29-1470320318755269]^ And this could be speculated as a key reason why the agent increased I~Na~ densities.

There is no significant difference in comparison of voltage-dependent inactivation of I~Na~ among the three groups, which is consistent with the previous study.^[@bibr6-1470320318755269]^ However, in human AF, myocardium in the inactivation curve was shifted to more positive voltages, which could increase sodium channel availability at the resting potential and increase CV.^[@bibr30-1470320318755269]^ There are many reasons contributing to these contrasting results of human and animal models of AF: differences of AF types (experimental vs. clinical AF), underlying cardiac disease, anti-arrhythmic drugs, or interspecies differences.

Li and colleagues demonstrated that imidapril hyperpolarized V~1/2inact~ of I~Na~ in rabbit ventricular myocytes.^[@bibr27-1470320318755269]^ Kim et al. reported that telmisartan significantly delayed the inactivation of the voltage-gated Na^+^ channel, causing cytosolic Na^+^ overload, prolonged AP duration, and subsequent Ca^2+^ overload in ventricular cardiomyocytes of male Sprague Dawley rats.^[@bibr31-1470320318755269]^ However, we did not find any difference in our data. We thus concluded that irbesartan did not have obvious effects on the inactivation characteristics of I~Na.~ Therefore, our conclusion varied from the above-mentioned one. The difference in conclusions might be caused by several issues, such as interspecies differences, differences in the animal models, time of drug administration, different drugs, or differences between atrial and ventricular myocardium. In addition, there was no alteration of slope factor κ~act~ and κ~inact~ shown in the three groups, which suggested that the intrinsic voltage of the channel was unaffected by pacing or drug treatment.^[@bibr29-1470320318755269]^

Study limitations {#section23-1470320318755269}
=================

One of the limitations of the present study is that we did not assess ventricular function using echocardiography. Since ventricular rate and blood pressure were not significantly changed by rapid atrial pacing among the three groups, ventricular tachycardia-induced left ventricular dysfunction likely did not have a significant effect on the results of these experiments. Furthermore, in our study only the left atria were analyzed. Therefore, responses of the right atrium to irbesartan remain unknown. Research on the sodium channel protein expression is still under way.

Conclusions {#section24-1470320318755269}
===========

Irbesartan is a powerful activator of atrial sodium channels by selectively shifting the voltage-activation relationship of I~Na~ to hyperpolarized potential or upregulating Nav1.5 mRNA expression. Therefore, irbesartan may contribute to the improvement of intra-atrial conduction and the prevention of induction and promotion of AF in atrial pacing dogs.
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